Integrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional biomarkers
Agenus Inc . ( Nasdaq: AGEN ), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program...
Medical Affairs scale-up supports France’s multi-tumor AAC access framework and expanding paid named-patient programs requests
Access to Acceleration: Agenus’ BOT+BAL Global Momentum Entering 2026 Webcast on Wednesday, January 28, 2026, at 4:00 p.m. ET
Agenus Inc . ( Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd....
Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings
Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population Findings reinforce the broad, pan-tumor activity...
Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET
Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as ...